New York, June 24, 2024 - PRISM MarketView - Clinical-stage biopharmaceutical company, Altimmune, Inc (Nasdaq: ALT) topped the PRISM Global Health Index on Monday morning after the company presented data from a 48-week Phase 2 clinical trial of pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate, in obesity. Altimmune’s share price rose by 17.69% in morning trading following the news.
Altimmune presented data that included the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. Full analysis of the body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat. The study enrolled 391 subjects with obesity, randomized to receive pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise.
“The preservation of lean mass observed in this trial was better than reported historically with diet and exercise programs and greater than what has been publicly reported with other incretin weight loss drugs, where lean mass has accounted for as much as 40% of total weight loss. Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function. We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.”
Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities